You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Your secondary AML treatment journey with VYXEOS

This section is designed to help you understand the length of your treatment with VYXEOS (vix-e-ose). Follow along to learn about important benchmarks and key terms that will help you feel more confident about what treatment may entail.

Before treatment

During treatment

VYXEOS is administered in 2 treatment phases, called induction and consolidation, as an intravenous (IV) infusion using a central IV line or peripherally inserted central catheter. You may receive up to 2 cycles of induction and up to 2 cycles of consolidation, depending on your treatment plan. Your healthcare team will determine what is needed for you.

Learn more about why multiple cycles of induction and consolidation may be needed.

1st induction

The first phase of treatment, known as first induction, is used to control the disease and reduce the number of leukemia cells (blasts) to achieve remission (a decrease in or disappearance of signs and symptoms of cancer). Most patients will require several weeks of hospital stay to monitor blood counts and manage potential complications.

  • Given in a 1-week time period
  • Days 1, 3, & 5 for 90 minutes

Days 14-21: Doctors may assess your bone marrow to see if VYXEOS is working by looking at how many blasts remain.

The next step will depend on the results of your bone marrow assessment. If there are still too many blasts left, you may begin 2nd induction. If your results show you are in remission, you may go directly to 1st consolidation.

2nd induction (if needed)

Second induction may be given if you did not reach remission after the first treatment.

  • Begins 2-5 weeks after 1st induction
  • Days 1 & 3 for 90 minutes

Days 14-21: You will have a bone marrow assessment.

Depending on the results of your bone marrow assessment, you may begin 1st consolidation.

1st consolidation

Consolidation is the next phase of treatment, used to maintain remission and decrease the number of remaining blasts. This phase will begin as soon as possible after recovery from induction.

  • Begins 5-8 weeks after start of last induction
  • Days 1 & 3 for 90 minutes

Days 14-21: Your doctors may perform follow-up tests to determine whether you need a 2nd consolidation.

2nd consolidation (if needed)

Second consolidation may be given to maintain remission.

  • Begins 5-8 weeks after start of 1st consolidation
  • Days 1 & 3 for 90 minutes

Your doctors may perform follow-up tests.

VYXEOS Treatment Journey

Want a printable copy of the information above to share or keep for your reference?

Download now

More treatment details


Although infusions do not occur daily, you will most likely be in the hospital for several weeks to monitor your blood count and manage any potential complications during treatment.


Second consolidation cycles are administered to ensure the disease remains controlled.


Your healthcare team may decide to administer VYXEOS in an outpatient setting based on the severity of the disease, your overall health, and how close you live to an infusion center. Your healthcare team will determine what is best for you.


Before consolidation can begin, doctors must assess cardiac function, complete blood counts, and liver and kidney function.


Absolute neutrophil count (ANC) and platelet count, which are measured with a blood test, will be assessed before consolidation to determine if consolidation is the next appropriate step.


The most common side effects reported by patients receiving VYXEOS include bleeding events, fever, rash, swelling, nausea, sores in the mouth or throat, diarrhea, constipation, muscle pain, tiredness, stomach pain, difficulty breathing, headache, cough, decreased appetite, irregular heartbeat, pneumonia, blood infection, chills, sleep disorders, and vomiting.

Helpful tips during AML treatment

Eye icon

Feelings of sadness, anxiety, and loneliness are normal during treatment.

Talk with your doctor about these concerns. Your healthcare team can provide you with sources of information and advice.

Hand icon

Accept support.

Reach out to family, friends, and any support groups that may be able to offer advice and solace for those going through chemotherapy.

Sun icon

Stay positive.

Chemotherapy can leave you feeling lonely and worried about the future. Continue your normal hobbies as much as possible. Reading, doing puzzles, journaling, and meditating may help you maintain a positive attitude.

Shoe icon

Stay physically active.

Take walks and engage in any fitness activities that are okayed by your doctor. Keeping your body in the best possible shape may help during treatment.

Apple icon

Eat healthy.

During chemotherapy, it is important to fuel your body with sources of vitamins and nutrients to keep energy levels steady.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.